Tedizolid: Difference between revisions
Created page with "{{intro}} Tedizolid is an oxazolidinone antibiotic, similar to linezolid, which has a broad spectrum of activity against gram positive bacteria including methicillin resis..." |
CSV import Tags: mobile edit mobile web edit |
||
| Line 18: | Line 18: | ||
{{antibiotics}} | {{antibiotics}} | ||
{{coststubd}} | {{coststubd}} | ||
<gallery> | |||
File:Tedizolid.svg|Tedizolid structure | |||
File:Tedizolid_phosphate.svg|Tedizolid phosphate structure | |||
</gallery> | |||
Latest revision as of 01:53, 17 February 2025
Information about Tedizolid[edit]
Tedizolid is an oxazolidinone antibiotic, similar to linezolid, which has a broad spectrum of activity against gram positive bacteria including methicillin resistant Staphyloccocal aureus (MRSA).
Liver safety of Tedizolid[edit]
Tedizolid has been associated with a low rate of transient serum aminotransferase elevations during therapy, but has not been linked to instances of clinically apparent acute liver injury.
Mechanism of action of Tedizolid[edit]
Tedizolid (te diz' oh lid) is a synthetic, second generation oxazolidinone antibiotic, similar to linezolid, that has broad bactericidal activity against gram positive organisms such as enterococci and staphylococci and most streptococci. Importantly, tedizolid has potent activity against Methicillin resistant strains of Staphyloccocus aureus (MRSA). Tedizolid acts by binding to the 50S subunit of bacterial ribosome, preventing the formation of the functional ribosomal 70S subunit and thereby blocking bacterial protein synthesis. In several randomized controlled trials, tedizolid was found to be similar in efficacy (“non-inferior”) to linezolid as therapy of acute bacterial skin and skin-structure infections.
FDA approval information for Tedizolid[edit]
Tedizolid was approved for use in the United States in 2014 and is currently indicated for treatment of skin and skin structure infections caused by susceptible bacteria, including Staphylococcus aureus. Because of its activity against multidrug resistant enterococci and staphylococci, the use of tedizolid is usually reserved for severe infections where methicillin or penicillin resistance is found.
Dosage and administration for Tedizolid[edit]
Tedizolid is available in tablets of 200 mg under the name Sivextro. It is also available as a powder in single dose vials for reconstitution in solution for intravenous administration. Tedizolid is typically given as a 6 day course of 200 mg once daily, either orally or intravenously.
{se}} Common minor side effects include nausea, diarrhea, abdominal upset, headache and arthralgias. Rare, but severe side effects that can occur with more prolonged therapy include serotonin syndrome, thrombocytopenia and optic and peripheral neuropathy.
-
Tedizolid structure
-
Tedizolid phosphate structure